![Sindre Hassfjell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 414 505 $ al 31/05/2026
Sindre Hassfjell is currently the Chief Technology Officer at Thor Medical ASA. Previously, he worked as the Director-Generator Development at Artbio AS.
He completed his undergraduate and graduate degrees at the University of Oslo in 1996 and 1997, respectively.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
THOR MEDICAL ASA 0,23 % | 02/03/2026 | 825.001 ( 0,23 % ) | 414 505 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| THOR MEDICAL | Director Técnico/Científico/I+D | 01/06/2023 |
| Empresas | Cargo | Fin |
|---|---|---|
Artbio AS
 Artbio AS BiotechnologyHealth Technology Operates as a clinical-stage radiopharmaceutical biotechnology business that works to create a new class of alpha radio ligand medicines | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
University of Oslo
 University of Oslo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Artbio AS
Artbio AS BiotechnologyHealth Technology Operates as a clinical-stage radiopharmaceutical biotechnology business that works to create a new class of alpha radio ligand medicines | Health Technology |
Thor Medical ASA
 Thor Medical ASA Miscellaneous Commercial ServicesCommercial Services Produces and supplies alpha particle emitters for cancer therapy | Commercial Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
Elige MarketScreener 
